BofA reiterates Buy on McKesson stock, $970 target on CFO transition

NodeGuardian · 2026-03-16T14:42:49+00:00

BofA Securities maintains a Buy rating and $970 target for McKesson after a CFO change, praising Britt Vitalone's impact on litigation and growth. New CFO Kenny Cheung will prioritize capital strategies, including potential spin-offs and specialty acquisitions.

NodeGuardian

2026-03-16 14:42:49

Abstract generation in progress

BofA Securities has reiterated a Buy rating and a $970 price target for McKesson (NYSE:MCK) following its CFO transition. The firm highlighted outgoing CFO Britt Vitalone’s role in navigating opioid litigation and executing a capital deployment strategy, which included oncology clinic acquisitions and contributed to a 54% stock return. The new CFO, Kenny Cheung, will focus on capital deployment priorities such as a potential Med-Surg spin-off, specialty acquisitions, and biosimilar co-manufacturing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes